Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38656167 | 1.00 | PDK2 (0.48) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL2898683 | 0.93 | PDK2 (0.47) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL29541692 | 0.77 | IMPDH2 (0.49) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL26259988 | 0.77 | MEN1 (0.48) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL26259975 | 0.77 | CYP11B1 (0.48) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL30570522 | 0.76 | MAP4K4 (0.49) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL4457202 | 0.76 | MAP4K4 (0.49) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL1363022 | 0.76 | NOTUM (0.50) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL1903692 | 0.76 | PDK2 (0.48) | PDK2NOTUMCYP11B1CYP11B2PTK2 | |
| SCHEMBL1328549 | 0.76 | GAA (0.50) | PDK2NOTUMCYP11B1CYP11B2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829559-B1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | MERCK SHARP & DOHME LLC (US) | 2025-06-17 | — | — | US | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3829559-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | Merck Sharp & Dohme Corp. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2020028150-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | MERCK SHARP & DOHME CORP. (US) | 2020-02-06 | — | — | WO | disclosed |
| WO-2012085857-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-3-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012085852-A1 | 3,8-DIAZA-BICYCLO[4.2.0]OCT-8-YL AMIDES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331044-B2 | Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection | HDAC1, HDAC11, HDAC10 | PDK2 997/4885NOTUM 2985/4885CYP11B1 1092/4885 |
| US-20210276992-A1 | INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION | HDAC1, HDAC11, HDAC10 | PDK2 997/4885NOTUM 2985/4885CYP11B1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.